Nexavar (sorafenib tosylate) — United Healthcare
renal cell carcinoma (RCC)
Initial criteria
- Diagnosis of renal cell carcinoma (RCC)
- AND one of the following:
- Disease has relapsed OR (Medically or surgically unresectable tumor AND Diagnosis of Stage IV disease)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Nexavar therapy
Approval duration
12 months